

LIST OF FIGURES

- Figure 4.1:** DPPH radical scavenging assay dose-response curve of ascorbic acid, Arab, UKMR-1 and UKMR-2 samples. Values are expressed as mean \pm SE and n=3.
- Figure 4.2:** Metal chelating assay dose-response curve of EDTA, Arab, UKMR-1 and UKMR-2 samples. Values are expressed as mean \pm SE and n= 3.
- Figure 4.3:** Reducing power assay dose-response curve of BHA, Arab, UKMR-1 and UKMR-2 samples. Values are expressed as mean \pm SE and n= 3.
- Figure 4.4:** Body weight of the animals treated with 1000 mg/kg body weight/ day of Arab, UKMR-1 and and UKMR-2 extracts.
- Figure 4.5:** Body weight of the animals treated with 1000 mg/kg body weight/ day of Arab, UKMR-1 and and UKMR-2 extracts
- Figure 4.6:** Cross section (200x) of kidney in mice in Normal Control group
- Figure 4.7:** Cross section (200x) of kidney in mice treated with 1000 mg/ kg body weight/day of Arab extract
- Figure 4.8:** Cross section (200x) of kidney in mice treated with 1000 mg/ kg body weight/day of UKMR-1 extract.
- Figure 4.9:** Cross section (200x) of kidney in mice treated with 1000 mg/ kg body weight/day of Arab extract.
- Figure 4.10:** Cross section (200x) of liver in mice Normal Control group
- Figure 4.11:** Cross section (200x) of liver in mice treated with 1000 mg/ kg body weight/ day of Arab extract
- Figure 4.12:** Cross section (200x) of liver in mice treated with 1000 mg/ kg body weight/ day of UKMR-1 extract
- Figure 4.13:** Cross section (200x) of liver in mice treated with 1000 mg/ kg body weight/ day of UKMR-2 extract
- Figure 4.14:** Cross section (200x) of kidney in mice in Normal Control group
- Figure 4.15:** Cross section (200x) of kidney in mice treated with 500 mg/ kg body weight/day of Arab extract.

- Figure 4.16:** Cross section (200x) of kidney in mice treated with 500 mg/ kg body weight/day of UKMR-1 extract.
- Figure 4.17:** Cross section (200x) of kidney in mice treated with 500 mg/ kg body weight/day of UKMR-2 extract.
- Figure 4.18:** Cross section (200x) of liver in mice Normal Control group
- Figure 4.19:** Cross section (200x) of liver in mice treated with 500 mg/ kg body weight/day of Arab extract.
- Figure 4.20:** Cross section (200x) of liver in mice treated with 500 mg/ kg body weight/day of UKMR-1 extract.
- Figure 4.21:** Cross section (200x) of liver in mice treated with 500 mg/ kg body weight/day of UKMR-2 extract.
- Figure 4.22:** Body weight of experimental animals in Normal control, Cholesterol control, Arab, UKMR-1 and UKMR-2 groups on day 0, 30th and 60th of experiment.
- Figure 4.23:** Triglyceride level in blood serum of experimental animals in various groups during 60 days of treatment. Values are expressed as mean \pm SE and n = 6.
- Figure 4.24:** Total cholesterol level in blood serum of experimental animals in various groups during 60 days of treatment. Values are expressed as mean \pm SE and n= 6.
- Figure 4.25:** HDL cholesterol level in blood serum of experimental animals in various groups during 60 days of treatment. Values are expressed as mean \pm SE and n=6.
- Figure 4.26:** LDL cholesterol level in blood serum of experimental animals in various groups during 60 days of treatment. Values are expressed as mean \pm SE and n= 6.
- Figure 4.27:** Intimal surface of the aortas from normal control group.
- Figure 4.28:** Intimal surface of the aortas from cholesterol control group of rabbits showing sudan IV stainable lipid deposit. Lipid deposits are stained brick red.

- Figure 4.29:** Intimal surface of the aortas from Arab extract treated group of rabbits showing sudan IV stainable lipid deposit. Lipid deposits are stained brick red
- Figure 4.30:** Intimal surface of the aortas from UKMR-1 group of rabbits showing sudan IV stainable lipid deposit.
- Figure 4.31:** Intimal surface of the aortas from UKMR-2 group of rabbits showing sudan IV stainable lipid deposit.
- Figure 4.32:** Full chromatograms of Arab variety in the positive mode
- Figure 4.33:** Chemical structure of gossypetin-3-O-glu-7-O-xylo/ara.
- Figure 4.34:** Fragmentation of herbacetin-8-O-xylo-3-O-glu: (A) Full chromatograms of Arab variety in the negative mode. (B) Fragmentation of peak at retention time 5.642 min results in a MS spectrum with m/z 300.0 dominating.
- Figure 4.35:** Molecular structure of herbacetin-8-O-xylo-3-O-glu
- Figure 4.36:** Full chromatograms of UKMR-1 variety in the positive mode.
- Figure 4.37:** Fragmentation of delphinidin-3-sambubioside: (A) Full chromatograms of UKMR-1 variety in the positive mode. (B) Fragmentation of peak at retention time 1.779 min results in a MS spectrum with m/z 303.0 dominating
- Figure 4.38:** Molecular structure of delphinidin-3-sambubioside.
- Figure 4.39:** Fragmentation of hibiscetin: (A) Full chromatograms of UKMR-1 variety in the positive mode. (B) Fragmentation of peak at retention time 1.46 min results in a MS spectrum with m/z 377.0 dominating.
- Figure 4.40:** Chemical structure for hibiscetine.
- Figure 4.41:** Fragmentation of delphinidin: (A) Full chromatograms of UKMR-1 variety in the positive mode. (B) Fragmentation of peak at retention time 6.15 min results in a MS spectrum with m/z 303.1 dominating
- Figure 4.42:** Molecular structure of delphinidine
- Figure 4.43:** Fragmentation of gossypetin: (A) Full chromatograms of UKMR-1 variety in the positive mode. (B) Fragmentation of peak at retention time 10.70 min results in a MS spectrum with m/z 319.2 dominating.
- Figure 4.44:** Molecular structure of gossypetin

- Figure 4.45:** Full chromatograms of UKMR-1 variety in the negative mode.
- Figure 4.46:** Fragmentation of herbacetin-8-O-xylo-3-O-glu: (A) Full chromatograms of UKMR-1 variety in the negative mode. (B) Fragmentation of peak at retention time 5.315 min results in a MS spectrum with m/z 595.1 dominating.
- Figure 4.47:** Molecular structure of herbacetin-8-O-xylo-3-O-glu.
- Figure 4.48:** Fragmentation of Quercetin rutinoside: (A) Full chromatograms of UKMR-1 variety in the negative mode. (B) Fragmentation of peak at retention time 5.798 min results in a MS spectrum with m/z 609.1 dominating.
- Figure 4.49:** Molecular structure of quercetin rutinoside
- Figure 4.50:** Full chromatograms of UKMR-2 variety in the positive mode.
- Figure 4.51:** Fragmentation of hibiscetin: (A) Full chromatograms of UKMR-2 variety in the positive mode. (B) Fragmentation of peak at retention time 1.785 min results in a MS spectrum with m/z 377.0 dominating.
- Figure 4.52:** Chemical structure of hibiscetin
- Figure 4.53:** Fragmentation of delphinidin: (A) Full chromatograms of UKMR-2 variety in the positive mode. (B) Fragmentation of peak at retention time 5.505 min results in a MS spectrum with m/z 303.1 dominating.
- Figure 4.54:** Molecular structure of delphinidine.
- Figure 4.55:** Fragmentation of herbacetin-8-O-xylo-3-O-glu: (A) Full chromatograms of UKMR-2 variety in the positive mode. (B) Fragmentation of peak at retention time 1.616 min results in a MS spectrum with m/z 303.1 dominating.
- Figure 4.56:** Molecular structure of herbacetin-8-O-xylo-3-O-glu
- Figure 4.57:** Fragmentation of quercetin-3-glucoside: (A) Full chromatograms of UKMR-2 variety in the positive mode. (B) Fragmentation of peak at retention time 11.923 min results in a MS spectrum with m/z 463.3 dominating.
- Figure 4.56:** Chemical structure of quercetin-3-glucoside